Path to Independence Program

The Path to Independence self-administration training program provides hands-on self-administration training, delivered by specially trained infusion nurses, to eligible patients who are receiving therapy with CINRYZE® (C1 esterase inhibitor [human]). A 2012 study found that of patients who received CINRYZE at home, 59% self-administered.

Here's how the program works:

  • A specially trained infusion nurse will visit your home, or location of choice (that both you and your doctor agree upon) to:
    • Conduct the necessary training on self-administration to assist you in how to safely and properly reconstitute and administer CINRYZE
    • Provide instruction on proper reconstitution and self-administration techniques
    • Determine if you are ready to self-administer CINRYZE independently
  • The infusion nurse will visit at a time that is convenient for you, including evenings and weekends. All aspects of this program are a complimentary service from OnePath®. There will be no cost to you or impact on your health plan benefits.

Do not attempt to self-administer unless you have been taught how by your healthcare provider.

Share Your HAE Knowledge

Spread awareness and help family and friends better understand HAE with the Awareness kit.

Learn more ›

Real Patients Talk About HAE

It helps to be reminded that you’re not alone. Hear first-hand stories from individuals who have HAE.

Hear their stories ›

CINRYZE® (C1 esterase inhibitor [human]) is an injectable prescription medicine that is used to help prevent swelling and/or painful attacks in teenagers and adults with Hereditary Angioedema (HAE).

Important Safety Information
You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis to the product.

Tell your healthcare provider about all of your medical conditions, including if you:

  • have an indwelling catheter/access device in one of your veins.
  • have a history of blood clots, heart disease, or stroke.
  • are taking birth control pills or androgens.
  • are pregnant or planning to become pregnant. It is not known if CINRYZE can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if CINRYZE passes into your milk and if it can harm your baby.

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

  • wheezing
  • difficulty breathing
  • chest tightness
  • turning blue (look at lips and gums)
  • fast heartbeat
  • swelling of the face
  • faintness
  • rash
  • hives

Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms:

  • pain and/or swelling of an arm or leg with warmth over the affected area
  • discoloration of an arm or leg
  • unexplained shortness of breath
  • chest pain or discomfort that worsens on deep breathing
  • unexplained rapid heart rate
  • numbness or weakness on one side of the body

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088. You can also report side effects to Shire Medical Information at 1-866-888-0660.

Please see the Full Prescribing Information.

Was this content
 useful to you?